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Helicobacter pylori: Prevalence and antibiotic susceptibility 
among Kenyans
Andrew Nyerere Kimang’a, Gunturu Revathi, Samuel Kariuki, Shahin Sayed, Smita Devani
Increasing evidence links infection of the gastric mucosa by 
Helicobacter pylori with the subsequent development of gastric 
pathologies. The incidence of H. pylori infection in Kenya 
is staggeringly high. An investigation into the prevalence 
of H. pylori in patients with dyspepsia and asymptomatic 
controls from the same population, showed high prevalence 
levels in both groups.1 Seropositivity for H. pylori was 
found in 98 (71%) symptomatic patients and in 70 (51%) 
asymptomatic participants. McFarlane et al. linked infection of 
the gastric mucosa by H. pylori in Kenya with the subsequent 
development of gastric atrophy.2 H. pylori prevalence in Kenya 
shows no difference between HIV-positive and -negative 
subjects.3. However, data on H. pylori antibiotic sensitivity 
profiles in Kenya are scarce because of lack of reliable and 
affordable media on which isolation and susceptibility testing 
of H. pylori can be performed.4-7 Lack of information on 
the susceptibility patterns of H. pylori strains implicated in 
infections leads to poor management, resulting in treatment 
failures. Resistance to metronidazole and clarithromycin 
has been reported to be highly prevalent and more common 
elsewhere.8 It is therefore important to find a medium that 
easily supports the growth of H. pylori and allows prompt 
susceptibility testing. We also investigated the prevalence of H. 
pylori infection in Kenya and associated disease outcomes.
Materials and methods
Patient population
We recruited 696 patients who had presented with dyspepsia 
at the gastroenterology clinic of the Aga Khan University 
Hospital, Nairobi, and who had been referred for endoscopy. 
They were all screened for H. pylori by the rapid urease and 
histological tests. Of the 696 patients, 70 (10%), who had 
positive stool antigen test prior to endoscopy and who had 
no history of antibiotic use in the 3 months preceding their 
visit to the clinic, were selected for H. pylori culture. The study 
was approved by the Aga Khan University Hospital Research 
and Ethics Committee. Biopsies (2 each from the antrum and 
corpus) were taken, submerged in 5% brain-heart-infusion agar 
(BHIA), enriched with 5% fetal bovine serum (FBS) and kept at 
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Background. Helicobacter pylori infection in Kenya is 
staggeringly high. Evidence links infection of the gastric 
mucosa by H. pylori with subsequent development of gastric 
pathologies.
Aim. We investigated the prevalence of H. pylori in dyspeptic 
patients, its relationship with gastric pathologies, and 
associated antibiotic susceptibility profiles, and compared two 
media to find the appropriate medium that enhances growth 
and expedites culture and isolation.
Methods. Rapid urease and histological tests were used to 
screen for H. pylori. Culture was performed to test sensitivity 
and evaluate media. Selective and nutritional supplements 
were added to culture media (Colombia blood agar and brain-
heart infusion agar) for growth enhancement. E-test strips for 
metronidazole, amoxicillin and clarithromycin were used for 
susceptibility testing.
Results. The prevalence of H. pylori infection in children was 
73.3%, and 54.8% in adults. All the H. pylori investigated in 
this study were largely sensitive to clarithromycin (100%, 
minimum inhibiting concentration (MIC) <2 µg/ml), 
amoxicillin (100%, MIC <2 µg/ml) and metronidazole (95.4%, 
MIC <8 µg/ml). There was, however, occasional resistance 
to metronidazole (4.6%, MIC >8 µg/ml). Both Colombia 
blood and brain-heart infusion agar, with the supplements, 
effectively supported H. pylori growth. Growth was achieved 
in an average of 36 hours for primary isolations and 24 hours 
for subcultures.
Conclusion. The media described here reduce the time 
required to culture and isolate bacteria and perform 
susceptibility testing. Despite the high prevalence of H. 
pylori infection, the associated pathology is low and does not 
parallel H. pylori prevalence in the population.
S Afr Med J 2010; 100: 53-57.
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4ºC till processing. All biopsies were processed within 3 hours 
of extraction.
Culture media preparation
Inactivation of fetal bovine serum
FBS to be used for culture media preparation was completely 
thawed at room temperature, transferred to a water bath at 
56°C and stirred manually every 10 minutes. When the FBS 
reached 56°C (indirectly measured by the temperature of the 
water bath), it was incubated for 30 minutes, cooled to room 
temperature, dispensed in aliquots of 35 ml into tubes labeled 
‘Inactivated FBS’, and stored at -20°C. Sterility control was 
performed by incubating an aliquot of the FBS at 37°C for 48 
hours.
H. pylori selective supplement (Dent) and nutritional 
supplement (Vitox)
To a bottle of Dent, 2 ml of sterile distilled water was added 
and mixed gently. The solution was used the same day. Vitox 
was prepared by mixing the provided solvent and the Vitox 
powder. All were prepared according to the manufacturers’ 
instructions.
Transport medium (5% BHIA + 5% FBS)
The above is the semi-solid agar for transportation of gastric 
biopsies. Five grams of BHIA was weighed, suspended in 
95 ml of sterile distilled water, dissolved by boiling, and 
subsequently autoclaved at 121°C for 15 minutes. After 
autoclaving, the medium was cooled to 45°C in a water-bath 
and gently mixed with a 5 ml aliquot of the inactivated FBS. 
Aliquots of 500 µl were dispensed into 1.5 ml tubes and stored 
at 4°C in a refrigerator until use. The transport medium was 
used within 1 week from the preparation date. A sterility 
control was done on one tube from the preparation under 
aerobic and micro-aerophilic conditions, at 37°C for 24 hours.
Non-selective culture media: Colombia blood agar (CBA) 
+ 7% FBS and BHIA + 7% FBS plates (CBA + 7% FBS and 
BHIA + 7% FBS)
CBA (19.5±0.1 g) and BHIA (23.5±0.1 g) (Oxoid, UK) were 
each weighed and put in separate 500 ml bottles. Both media 
were suspended in 500±0.5 ml sterile distilled water and fully 
dissolved by boiling. These bottles were labeled ‘CBA + 7% 
FBS’ and ‘BHIA + 7% FBS’ respectively and autoclaved at 
121°C for 15 minutes. After autoclaving, the media were cooled 
to 45°C in a water-bath and gently mixed with 35 ml aliquots 
of the inactivated FBS and the Vitox supplement. The media 
were poured (approximately 25 ml per plate), left to solidify, 
and dried at room temperature for 2 hours before being stored 
at 8°C in a refrigerator until use. The plates were used within 
1 week from the preparation date. Sterility control on 2 plates 
from each pack of 20 plates was done at 37°C for 24 hours, 1 
under aerobic and 1 under micro-aerophilic conditions.
Selective culture media: CBA + 7% FBS + Dent, and BHI agar 
+ 7% FBS + Dent plates (CBAD + 7% FBS and BHIAD + 7% 
FBS)
(CBAD = Colombia blood agar with Dent selective supplement 
containing vancomycin, trimethoprim, cefsulodin and 
amphotericin B; BHIAD = brain-heart-infusion agar with Dent 
selective supplement containing vancomycin, trimethoprim, 
cefsulodin and amphotericin B.)
CBA (19.5±0.1 g) and BHIA (23.5±0.1 g) (Oxoid, UK) were 
each weighed and put in separate 500 ml bottles. Both media 
were suspended in 500±0.5 ml of sterile distilled water and 
were fully dissolved by boiling. These bottles were labelled 
‘CBAD + 7% FBS’ and ‘BHIAD + 7% FBS’ respectively, 
autoclaved at 121°C for 15 minutes, cooled down to 45°C 
in a water-bath, and gently mixed with the inactivated FBS; 
thereafter, Dent and Vitox were added and mixed by gently 
rolling the bottle. The media were poured (approximately 25 
ml per plate), left to solidify, and dried at room temperature for 
2 hours before being stored at 8°C in a refrigerator until use. 
The plates were used within 1 week from the preparation day. 
Sterility control at 37°C for 24 hours on two plates from each 
pack of 20 plates was done; 1 under aerobic and 1 under micro-
aerophilic conditions.
H. pylori growth
The biopsies were transferred by sterile 1 000 µl pipette to 
clean sterile tubes, where they were completely crushed using 
the pipette tip; 200 µl of BHI broth, enriched with 5% FBS, was 
added and uniformly mixed. Next, 100 µl of the ruptured and 
homogenised material was aseptically transferred to each of 
the appropriately labelled plates, one selective and the other 
non-selective, using a disposable 10 µl sterile inoculating loop. 
The inoculum was aseptically spread on the surface of the 
plates. Inverted, the plates were placed in a 2.5 l jar. A Campy 
Micro-aerophilic kit was added, and the jar immediately closed 
and incubated undisturbed at 37°C for 3 days. After 3 days, 
the plates were removed and visually inspected. When the 
colonies appeared too small, a new Campy Micro-aerophilic 
kit was placed in the 2.5 l jar and the plates re-incubated 
immediately for a further 2 days. If growth was not satisfactory 
after 5 days, further incubation was done up to 7 days with 
a new Campy Micro-aerophilic kit until the colonies were 
well visible. H. pylori identification was confirmed by colony 
morphology, Gram-stain, and oxidase, urease and catalase 
positivity. Old cultures were a mixture of short rods and 
coccoids, while young cultures were curved rods. Subcultures 
were done on antibiotic-free media. Pure culture was harvested 
by transferring 200 µl phosphate-buffered saline (PBS) onto the 
plate. The pure bacteria growth on the plate was emulsified 
in the PBS using a sterile inoculating loop. The suspension 
was then transferred to cryotubes containing 500 µl BHI broth 
enriched with 20% glycerol and 5% FBS, and stored at -80OC.
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H. pylori sensitivity testing
A frozen vial of the correctly identified H. pylori was thawed 
at room temperature and mixed by pippeting up and down 
with a micropipette. This sample was used for subculture. 
Young, pure cultures were harvested by transferring 200 µl 
PBS onto the culture plate and the bacteria emulsified into a 
suspension using a sterile inoculating loop. The suspension 
was collected into a sterile tube and a McFarland’s turbidity 
standard no. 3 made for use in susceptibility testing. The 
inoculum was aseptically spread over the entire portion of the 
surface of the sensitivity test plate, and allowed to stand at 
room temperature for 10 minutes before the antibiotic E-test 
strips for clarithromycin (0.016-256); metronidazole (0.002-32) 
and amoxicillin (0.016-256) were applied. Inverted inoculated 
plates were then placed into the jar. One envelope of Campy 
Micro-aerophilic gas kit was put into the 2.5 l jar following 
the manufacturer’s instructions. The jar was incubated at 37°C 
for 24 hours, and then removed and inspected for satisfactory 
H. pylori growth. If the growth were insufficient, the plates 
were immediately put back into the jar with a new CampyGen 
Micro-aerophilic gas kit, and incubation continued at 37°C for a 
further 12 hours. When growth was satisfactory, the minimum 
inhibiting concentration (MIC) for each antibiotic was read 
as recommended by the National Committee on Clinical 
Laboratory Standards/Clinical and Laboratory Standards 
Institute (NCCLS/CLSI) standards.
Results
Of the 696 patients with dyspepsia who were screened, 66.1% 
were adults and 33.9% were children. The prevalence of H. 
pylori infection in the adult segment was 54.8%; and 73% in 
children (Fig. 1). Culture was attempted on 70 biopsies; of 
these, 65 (92.8%) were successful.
Prevalence of H. pylori infection was 65% in African 
immigrants, 25% in Asian immigrants, 56% in rural Kenyan 
Africans, 62% in urban Kenyan Africans, and 58% among 
urban Kenyan Asians. Gastro-esophageal reflux disease 
(GERD) accounted for 201 (28.9%) of the cases, gastric polyps 
3 (0.4%), atrophic mucosa 4 (0.6%), gastric cancer 6 (0.9%), 
gastritis 452 (64.9%), duodenal ulcer 12 (1.7%), and gastric ulcer 
18 (2.6%) (Fig. 2). GERD was more common in Kenyan female 
patients (56 - 65.6%) than males.
Gastric and duodenal ulcers occur with equal frequency in 
all racial groups. Despite a high prevalence (67.5%) of H. pylori 
in Kenya, the complicated disease outcomes (such as gastric 
cancer) are relatively low in this series (Table I).
Results of susceptibility testing for metronidazole (MZ), 
amoxicillin (AX) and clarithromycin (CL) and the total number 
of H. pylori bacilli susceptible at different concentration of these 
drugs are summarised in Fig. 3. MIC levels of <8 µg/ml for MZ 
and AX, and <2 µg/ml for CL, were interpreted as sensitive.
All the H. pylori that we investigated were largely sensitive 
to clarithromycin (100%), amoxicillin (100%) and metronidazole 
(95.4%). However, there was occasional resistance to 
metronidazole (4.6%). The 3 antibiotics showed no significant 
difference in activity (mean±SD: MZ 5±8.6, CL 5±7.3, AX 
5±5.3, p=1). Both CBA and BHIA effectively supported H. 
Fig. 2. Major endoscopic findings.
GERD = gastro-oesophageal reflux disease; POLY = gastric polyp; AM = atrophic mucosa; CA
= gastric cancer; DU = duodenal ulcer; GU = gastric ulcer.
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Fig. 1. Percentage of cases investigated and corresponding H. pylori prevalence.
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Fig.4. Antibiotic sensitivity profiles.
Antibiotic Susceptibility Profiles
0
5
10
15
20
25
30
35
0.0
16
-0.
12
5
0.1
26
-0.
25
0.2
6-
0.5
0.6
-0.
75
0.7
6-
1
1.2
5
1.2
6-1
.75
1.7
6-
2 3 4 5 >8
MIC Leves
N
um
be
ro
fB
at
er
ia
pe
rM
IC
C
at
eg
or
y
MZ
CL
AX
Fig. 3. Antibiotic sensitivity profiles.
January 2010, Vol. 100, No. 1  SAMJ
ORIGINAL ARTICLES
56
pylori growth achieved in an average of 36 hours for primary 
isolations and 24 hours for subcultures (data not shown).
Discussion
Prevalence of H. pylori was found to be 67.5% in all age 
groups (73.3% in children and 54.8% in adults), similar to the 
findings of Shmuely et al,1 who documented 60 - 73% in all 
age groups in dyspeptic patients. However, this finding differs 
with studies in other African countries which found H. pylori 
prevalence levels of >90%.9-13 Gastritis accounted for the largest 
proportion (64.9%) of the H. pylori-associated pathologies, as 
found elsewhere in Africa.9 It has been noted that, despite 
the prevalence of a virulent strain and high prevalence of 
H. pylori, the associated pathology (duodenal ulcer, gastric 
ulcer and gastric cancer) is variable and often low-incidence, 
and its distribution in sub-Saharan Africa does not parallel 
H. pylori prevalence in the population.14,15 This phenomenon 
was strongly supported by the findings of our study, where 
atrophic mucosa represented 0.6%, gastric cancer 0.9%, 
duodenal ulcer 1.7%, and gastric ulcer 2.6% of all observed 
pathologies, despite the high prevalence (67.5%) of H. pylori 
infection, which implies that, in this decade, the old status quo 
still stands.
We found no difference in the distribution of H. pylori 
pathologies among the different ethnic inhabitants of Kenya. In 
2001, Segal et al.14 reported that, despite the presence of virulent 
strains in Africa, associated pathologies are not in tandem. 
He suggested that host immune response may be a factor in 
protecting against development of gastric cancer. Our findings 
seem to suggest otherwise. If host immune response were a 
factor, we should see a varied distribution of pathologies in 
our study population of different ethnic groups. Therefore, we 
suggest that the development of significant clinical pathology 
in H. pylori infection depends on a combination of complex 
factors, possibly host genetics, environment, pathogens and age 
of the host.
All the H. pylori investigated in this study were largely 
sensitive to clarithromycin (100%), amoxicillin (100%) and 
metronidazole (95.4%). There was, however, occasional 
resistance to metronidazole (4.6%). The 3 antibiotics showed 
no significant difference in activity (mean±SD: MZ 5±8.6, CL 
5±7.3, AX 5±5.3, p=1). Susceptibility rates in Cameroon were 
found to be 55.3% for clarithromycin, 14.4% for amoxicillin 
and 6.8% for metronidazole.13 The documented resistance of 
amoxicillin in Africa signifies the emergence of H. pylori strains 
resistant to this key component in H. pylori treatment protocols. 
Up to the year 2000, amoxicillin-resistant H. pylori strains 
had rarely been detected, with a total of only 14 reported.16 
Significantly, complete loss of the resistant phenotype was 
observed after these strains were stored at -80°C, owing to 
the process of freezing and thawing. Only one amoxicillin-
resistant H. pylori strain had been isolated, in the Netherlands, 
in which amoxicillin resistance remained stable after repeated 
cycles of freezing and culture.17 The MIC for this strain 
was 8 µg/ml, which is relatively low. A survey is therefore 
necessary to confirm the presence of amoxicillin-resistant H. 
pylori strains in Africa. Amoxicillin-resistant H. pylori strains 
in circulation are a threat to public health, as this resistance 
trait may be transferable to amoxicillin-susceptible strains,17 
presumably owing to DNA exchange by transformation or a 
conjugation-like mechanism.18 Our study, however, shows a 
high susceptibility to amoxicillin among H. pylori strains.
The media we described support H. pylori growth in an 
average of 36 hours for primary isolations and 24 hours for 
subcultures, with an isolation rate of 92.8% (65/70) whereas an 
isolation rate of 47% (31/66) in Kenya was achieved in growth 
using Modified Thayer-Martin agar after 4 days of incubation.4 
The medium used in this study is therefore considered superior 
and can be used for enhanced cultivation of H. pylori and 
susceptibility testing.
Lastly, the great diversity of ethnic and racial groups in 
Kenya, and the high prevalence of H. pylori but the low 
prevalence of gastric carcinoma, call for closer examination of 
H. pylori in different regions and ethnic groups within Kenya 
as well as within surrounding regions. This investigation can 
provide new data regarding both the diversity of H. pylori as 
well as the co-migration of H. pylori and its human hosts.
This study was funded by the Deutscher Akademischer Austausch 
Dienst (German Academic Exchange Service) (DAAD), and 
Table I. Racial/regional groupings and disease outcome
Race/regional 
background           N (%) GERD           POLY            AM   CA       Gastritis   DU         GU
African immigrant           49 (7) 12 (24.5)           0 (0)              0 (0)   1 (2)       34 (69.4)   1 (2)         1 (2)
Asian immigrant           14 (2) 7 (50)           0 (0)              0 (0)   0 (0)       6 (42.9)   0 (0)         1 (7)
Kenyan-African rural        186 (26.7) 63 (33.9)           1 (0.5)           4 (2.2)   2 (1.1)       106 (57)   4 (2.2)         6 (3.2)
Kenyan-African urban       319 (45.8) 69 (21.6)           0 (0)              0 (0)   3 (0.9)       237 (74.3)   4 (1.3)         6 (1.9)
Kenyan-Asian urban         69 (9.9) 25 (36.2)           2 (2.9)           0 (0)   0 (0)       37 (53.6)   2 (2.9)         3 (4.3)
Others            59 (8.5) 25 (42.4)           0 (0)              0 (0)   0 (0)       32 (54.2)   1 (1.7)         1 (1.7)
Total            696  201 (28.4)           3 (0.4)           4 (0.6)   6 (0.9)       452 (64.9)   12 (1.7)         18 (2.6)
GERD = gastro-oesophageal reflux disease; POLY = gastric polyp; AM = atrophic mucosa; CA = gastric cancer; DU = duodenal ulcer; GU = gastric ulcer.
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was supported by the Aga Khan University Hospital and Jomo 
Kenyatta University of Agriculture and Technology, Nairobi, 
Kenya.
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